Non-small cell lung cancer+1
RecruitingA Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation
A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation
- Disease:Non-small cell lung cancerLung neoplasm malignant
- Substances:CarboplatinCisplatin+3
Belgium- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Merck Sharp & Dohme LLC













